Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Irish people are more willing to get vaccines than people in many other countries, though there is a “sizeable minority” ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

However, many aspects of how mRNA functions at the cellular level remained unresolved. The new findings address some of those unanswered questions, drawing attention from the global scientific ...

However, many aspects of how mRNA functions at the cellular level remained unresolved. The new findings address some of those unanswered questions, drawing attention from the global scientific ...

One in five Irish people said they would not take a traditional vaccine, a worldwide research project found. A further one in ...

Measles, once virtually wiped out in the United States, could become commonplace again if declining vaccination rates ...

Concerned that the nation’s health leadership is casting unfounded doubt on the safety of well-studied vaccines and may take ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

In March, short sellers collectively increased their negative bets on the broader healthcare industry. Read more details here ...

The EXTRAClean Exosomal RNA Isolation Kit produces high-quality RNA that improves results from small RNA sequencing and ...